CYP2D6 Genotyping and the use of tamoxifen in breast cancer1

Journal of the National Cancer Institute

Volumn 105, Issue 17, 2013, Pages 1267-1269

  Berry, Donald ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DNA; TAMOXIFEN;

ALLELE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL PRACTICE; EDITORIAL; GENOTYPE; HETEROZYGOSITY LOSS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MEASUREMENT ERROR; PRIORITY JOURNAL;

BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; DNA, NEOPLASM; FEMALE; HUMANS;

EID: 84884494850     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt221     Document Type: Editorial

References (15)

1. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97(1):30-39.
2. Regan MM, Leyland-Jones B, Bouzyk M, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 2012;104(6):441-451.
3. Rae JM, Drury S, Hayes DF, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104(6):452-460.
4. Kelly CM, Pritchard KI. CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned. J Natl Cancer Inst. 2012;104(6):427-428.
5. Nakamura Y, Ratain MJ, Cox NJ, et al. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst. 2012;104(16):1264.
6. Pharoah PDP, Abraham J, Caldas C. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104(16):1263-1264.
7. Stanton V Jr. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst. 2012;104(16):1265-1266.
8. Regan MM, Bouzyk M, Rae JM, Viale G, Leyland-Jones B. Author response. J Natl Cancer Inst. 2012;104(16):1266-1267.
9. Rae JM, Hayes DF, Cuzick J, Sestak I, Dowsett M. Author response. J Natl Cancer Inst. 2012;104(16):1267-1268.
10. Kelly CM, Pritchard KI. Author response. J Natl Cancer Inst. 2012; 104(16):1268.
11. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. Lancet. 2011;378(9793):771-784.
12. Terasawa T, Dahabreh I, Castaldi PJ, Trikalinos TA. Systematic reviews on selected pharmacogenetic tests for cancer treatment: CYP2D6 for tamoxifen in breast cancer, KRAS for anti-EGFR antibodies in colorectal cancer, and BCR-ABL1 for tyrosine kinase inhibitors in chronic myeloid leukemia. technology assessment report for Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (HHSA 290 2007 100551). June 2010). http://www.cms.gov/Medicare/ Coverage/DeterminationProcess/downloads/id76ta.pdf. Accessed July 6, 2013.
13. Brauch H, Schroth W, Goetz MP, et al. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol. 2013;31(2):176-180.
14. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23(36):9312-9318.
15. Rae JM, Regan MM, Thibert JN, et al. Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst. 2013;105(17):1332-1334.